NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

Core Viewpoint - NuCana plc has successfully canceled all remaining Series A Warrants, raising the necessary capital through its at-the-market offering, thereby eliminating overhanging rights from its May 2025 registered direct offering [1][2]. Company Overview - NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes using its ProTide technology to enhance the efficacy and safety of widely prescribed chemotherapy agents [3]. - The company's pipeline includes NUC-7738, a novel anti-cancer agent in Phase 2 studies, and NUC-3373, currently in a Phase 1b/2 modular study, both targeting advanced solid tumors [3].